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Comparative Genome Analysis of Ciprofloxacin-Resistant
Pseudomonas aeruginosa Reveals Genes Within Newly
Identified High Variability Regions Associated With Drug
Resistance Development
Hsun-Cheng Su,1,* Jainab Khatun,2 Dona M. Kanavy,1,{ and Morgan C. Giddings1,2,{
The alarming rise of ciprofloxacin-resistant Pseudomonas aeruginosa has been reported in several clinical studies.
Though the mutation of resistance genes and their role in drug resistance has been researched, the process by
which the bacterium acquires high-level resistance is still not well understood. How does the genomic evolution
of P. aeruginosa affect resistance development? Could the exposure of antibiotics to the bacteria enrich genomic
variants that lead to the development of resistance, and if so, how are these variants distributed through the
genome? To answer these questions, we performed 454 pyrosequencing and a whole genome analysis both
before and after exposure to ciprofloxacin. The comparative sequence data revealed 93 unique resistance
strain variation sites, which included a mutation in the DNA gyrase subunit A gene. We generated variation-
distribution maps comparing the wild and resistant types, and isolated 19 candidates from three discrete
resistance-associated high variability regions that had available transposon mutants, to perform a ciprofloxacin
exposure assay. Of these region candidates with transposon disruptions, 79% (15/19) showed a reduction in the
ability to gain high-level resistance, suggesting that genes within these high variability regions might enrich for
certain functions associated with resistance development.
Introduction
Antibiotics were once considered a ‘‘magic bullet’’ inthe war with infectious pathogens. However, the misuse
of antibiotics is now leading to increased drug resistance,
which threatens the effective treatment and prevention of
bacterial infections,18 especially for patients with chronic dis-
eases, such as Cystic Fibrosis (CF), who are exposed to anti-
biotics more frequently, drug resistance is a common yet
serious problem. Pseudomonas aeruginosa (PA) is a major
pathogen in the CF lung, and once acquired, chronic infection
will almost always ensue.20,23 The biggest challenges in com-
bating PA are its innate resistance to many antibiotics and its
ability to acquire higher levels of resistance after exposure to
antibiotics. Medications that doctors often use as their first
defense in treating lung infections in CF, such as ciprofloxacin
and tobramycin, have become less effective on PA.12,17,27
Studies on ciprofloxacin resistance to date have focused on
themutation of DNA gyrase/topoisomerase IV1,11,22,29 and the
efflux pump regulatory genes mexR and nfxB.16 However, the
series of steps andmolecular mechanisms that make antibiotic-
susceptible bacteria become antibiotic-resistant still remain a
mystery. Recently, Breidenstein et al. screened for mutants that
exhibited an altered susceptibility using the PA14 comprehen-
sive mutant library to reveal the extent of the ciprofloxacin
‘‘resistome’’ in PA.6 However, a survey result based on indi-
vidual mutants alone may not show the complete picture of
PA’s complex responseswhen it is exposed to ciprofloxacin. Ina
previous study, we found that when PA was continuously ex-
posed to ciprofloxacin during its stationary growth phase (i.e.,
up to 48hr), PA acquired the drug resistance in a multistage
process.26Ourdata indicated that resistancedevelopment inPA
is not the result of a preexisting resistance in the population, nor
is it developed in a single genemutation event. Instead, thedata
suggested that preexisting cellular pathways, protein modifi-
cation regulation, and single nucleotide gene mutations each
support the resistance development process, such that high-
level resistance in PA is a stepwise, ratcheting up process.26
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Though microarray analyses of changes in gene expression5
and changes in protein profiles2 have been performed, the
possible link between genomic variation in PA and resistance
development has not been evaluated, especially after PA has
been exposed to an antibiotic. If evidence suggests that high-
level ciprofloxacin resistance is not preexisting but rather the
result of a series of adaptive steps that produce variants, we
hypothesized that those adaptive variants may provide a fit-
ness advantage for the newly developed resistant strain. Here
we examined the genome of the susceptible wild type strain
and its derivative resistant strain using high throughput se-
quencing technology (454/Roche Applied Science). High
throughput next-generation sequencing technology provides
an opportunity to examine these postexposure genomic vari-
ations, which can enhance our knowledge of the evolutionary
driving forces in PA’s resistance development. In this report,
we aim to explore the potential evolutionary variants and
their distribution throughout the PA genome, after the bac-
teria has been exposed to antibiotics.
Materials and Methods
Materials and equipment
We used Luria agar base Miller (LA) medium (TEKnova,
Inc.) and Luria broth base Miller (LB; Acros Organics) from
Fisher Scientific. Ciprofloxacin, 3-[(3-cholamidopropyl)-di-
methylammo- nio]-1-propanesulfonate, iodoacetamide, and
dithiothreitol were procured from Sigma-Aldrich. We used
the QIAGEN Genomic-tip 20/G & Genomic DNA Buffer set
(QIAGEN), and Qubit Fluorometer and Quant-iT dsDNA
High-Sensitivity Assay Kit (Invitrogen). Genome sequencing
was carried out with a 454 Life Sciences Genome Sequencer
FLX instrument (Roche Applied Science) located in the UNC
High Throughput Sequencing Facility.
Bacterial strains, media, culture conditions,
and minimal inhibitory concentration assays
P. aeruginosa PAO1 was obtained from the University of
Washington (UW) Genome Center, and UW’s transposon
mutant library was the source of all PA mutants used in this
study.15All liquid cultureswere grown at 35Cwith aeration in
a 500-ml Erlenmeyer flask with 50ml of LB medium and sup-
plemented with ciprofloxacin where indicated; the culture on
LA medium with ciprofloxacin was grown for 48hr at 35C
and then colony-forming units were counted. The cell culture
inoculation and ciprofloxacin exposure were performed fol-
lowing our previously established methods.26 Minimal inhib-
itory concentrations (MICs) were determined by Etest (AB
bioMe´rieux, AB Biodisk), using the prescribed protocol. The
ciprofloxacin-resistant P. aeruginosa PAO1-CipR (in our previ-
ous paper26 we named it PAO1-6) was a derivative strain of the
susceptible wild type PAO1 after 48hr of exposure.
DNA extraction and purification
The origins of the PA strains from which the genome was
sequenced are presented in Table 1. Stocks for these strains
were stored at - 80C in LB broth with 15% glycerol. Freezer
stocks were streaked on LA agar, and single colonies were
picked to inoculate in 3ml LB. These cultures were grown for
18 hr at 35C with shaking at 150 rpm. DNA was extracted
from 1ml culture (around 4 · 109 cells) using QIAGEN
Genomic-tip 20/G & Genomic DNA Buffer set according to
the manufacturer’s instructions. DNA was eluted with 100 ml
buffer EB (Qiagen) and stored at - 20C.
454 pyrosequencing and sequence analysis
Purified genomic DNA was quantified using a Quant-iT
dsDNA High-Sensitivity Assay Kit (Invitrogen). Pyrosequen-
cing was carried out using a 454 Life Sciences Genome
Sequencer FLX instrument (Roche Applied Science).
A library of single-stranded template DNA fragments was
prepared from the purified genomic DNA using the GS FLX
Standard DNA Library Preparation Kit. The GS FLX Standard
emPCR Kit I (Shotgun) was used for emulsion-based clonal
amplification of a single-stranded template DNA library. The
GS FLX Standard LR70 Sequencing Kit was used in combi-
nation with the GS FLX Standard PicoTiterPlate Kit to deter-
mine the nucleotide sequence of the immobilized and clonally
amplified DNA library. All kits (Roche Applied Science) were
used according to the manufacturer’s instructions. We used
the P. aeruginosa PAO1 complete genome (accession number
NC_002516.2; GI 110645304) as a reference to assemble the
genome and used GS Reference Mapper (454 runAssembly
software, Version 2.3) to map and identify variants.
The DNA sequence annotation was visualized by Artemis
(www.sanger.ac.uk/resources/software/artemis), and the
Artemis Comparison Tool (ACT) (www.sanger.ac.uk/
resources/software/act) was used as the DNA sequence
Table 1. General Features of the Pseudomonas aeruginosa Genomes in This Study
Features PAO1 (Wild type) PAO1-CipR (Resistant) Ref-PAO1 (NC_002516.2)
Sequencing average depth 11.3 · 12.0 ·
Average sequence read length 371.0 379.0
Total number of reads 193626 202473
Total number of bases 71596070 76408394
Number of mapped bases 71332133 76059650
Number of fully mapped 189055 (97.64%) 197414 (97.50%)
Number of partially mapped 1162 (0.6%) 1308 (0.65%)
Number of unmapped 319 (0.16%) 381 (0.19%)
Number of contigs 862 1705
Number of assembled bases 6061093 5802470 (genome bases) 6264404
% Guanine-Cytosine content 66%
% Coding 89%
Gene 5682
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comparison viewer. The genome sequence comparison infor-
mation was analyzed and results were visualized using the
GView Server (http://server.gview.ca/gview-server/). JMP
9.0 (www.jmp.com/software/jmp9) was used for statistical
analysis and for visualizing the genomic variation distribution.
Bacterial strain selection for sequencing
Starting with our collected PAO1 strain, after 48 hr of con-
tinuous ciprofloxacin exposure at 4· the startingMICof0.5mg/
ml,we collected all surviving cells and transferred them into the
fresh medium without adding further antibiotics. By further
MIC screening, we isolated a ciprofloxacin-resistant PAO1-
CipRstrain,whose ciprofloxacin resistance increasedalmost 50-
fold to an MIC of 24mg/ml—a clinically significant level. We
then used this resistant strain in our study to evaluate the rela-
tionship between genomic variation and resistance develop-
ment.
Overview of genome sequencing data for PAO1-CipR
To better understand the genetic basis of the increasing
ciprofloxacin resistance in PAO1-CipR, the whole genomes of
PAO1-CipR and its original wild type PAO1 were sequenced
(Table 1). The reference genome of PAO1 (NC_002516.2) has a
circular chromosome consisting of 6,264,404 bp with an aver-
age G+C content of 66%. The draft genome sequences for
resistant PAO1-CipR and wild type PAO1 were obtained
using 454 pyrosequencing with shotgun libraries.
Selecting candidates for ciprofloxacin resistance assay
In this study, we applied low stringency criteria to un-
cover a greater number of potential variants for further
study. For a variant to be selected for this study, it must have
had a minimum of: (1) two reads and (2) a 10% variation
frequency. We performed a statistical analysis of the genomic
variation distribution between the wild type and the resis-
tant type using JMP 9.0 software, to find the regions that
were altered in the resistant strain. Using the ‘‘distribution’’
function in JMP, we designated the genomic variation sites as
the ‘‘x column’’ input, and the frequency variation of each
variant as the ‘‘weight’’ input. We then set a 200,000 bp se-
quence window as the increment for visualizing the varia-
tion distribution through the whole genome. A smooth curve
(a nonparametric density curve by kernel regression) was
also generated for each distribution map (Fig. 1A). Variants
with variation frequencies over 80% were selected, and their
associated regions, having a continuous variation probability
over 3% (i.e., the average sum of variation frequencies within
a fixed 200,000 bp sequence window), were defined as the
high variability regions in this study.
After noting the established variation profiles and identify-
ing the gene variation candidates within the high variability
regions, we then checked the availability of PA transposon
mutants fromUWGenomeCenter, and requested specific gene
knockout strains for further ciprofloxacin resistance assay.
Results
Comparative genomic analysis of PAO1-CipR and PAO1
The PAO1-CipR genome assembly yielded 1705 contigs
with a total 12-fold sequencing average depth, while our
collected wild type PAO1 genome assembly yielded 862
contigs with a total 11.3-fold sequencing average depth (all
sequenced contigs have been deposited at GenBank under
the accession PRJNA202063/ASJG00000000 & PRJNA201024/
ASJY00000000). Interestingly, despite the fact that resistant
PAO1-CipR had higher overall total read numbers, we found
that it had more unmapped read sequences (381 vs. 319) and
fewer assembled total bases (5,802,470 bp vs. 6,061,093 bp),
when compared to the wild type PAO1. Those data indicated
that PAO1-CipR had more un-closed sequence gaps than its
original wild type PAO1, which may have been caused by
multiple DNA insertions/deletions.25 To discover more pu-
tative variants, we applied a low stringency approach that
allowed a variant to be identified based on a very small
number of reads (i.e., two reads). In cases of low read counts,
sequencing errors can have a greater influence on the data,
and so should be interpreted with caution in these cases. Both
PAO1-CipR and the original wild type strain showed a total
of 204 common variants when compared to the reference PA
genome (NC_002516.2) (Supplementary Table S1; Supple-
mentary Data are available online at www.liebertpub.com/
mdr). The sequence variation frequency refers to how many
times a variant was observed from 454 pyrosequencing reads
differed from the reference sequence, and a minimum varia-
tion frequency of 10% was considered necessary to indicate
the presence of a variant. Along with the common variants, an
additional 93 unique variants appeared in the PAO1-CipR
genome sequence, including 18 genomic variants located in
noncoding regions. Moreover, we found a genomic variation
site located in the gyrA gene of PAO1-CipR: this is noteworthy
because the gyrA gene mutation is suspected to be a primary
factor responsible for ciprofloxacin resistance in PA.11–13,16,29
Our collected wild type genome sequence showed a total of 88
unique variants (sequence variation frequency ranging from
10%–*100%), 23 of which were located in noncoding regions
(see Supplementary Table S1 for all variant information).
The comparison of genomic variation distribution
The 454 pyrosequencing method that we used in this study
is based on the ‘‘sequencing by synthesis’’ principle,14,21,24 a
technique for accurate and quantitative analysis of DNA se-
quences. We used this technique to observe and evaluate the
DNA synthesis process inside PAO1 and PAO1-CipR, thereby
distinguishing their genomic variation differences. With that
genomic variation information in hand, we could then ex-
amine if the variations were involved in high-level resistance
development through a gene knockout experiment.
Though we recognize that 454 pyrosequencing data differ
from traditional Sanger chemistry sequencing data, and that
these differences could affect downstream applications, such
as the detection of rare mutations,3,7,9,28 previous reports
revealed that most variations detected by 454 pyrosequen-
cing were not detected by Sanger clone-based sequencing.19
To estimate nucleotide diversity, we considered a minimum
variation frequency of *10% to indicate potential variants.
We first generated genomic variation distribution maps
for both the wild type and the resistant type using JMP 9.0
software. These variation distribution maps show that for
both the wild type and the resistant genomes, the most
abundant variants (*35% probability for wild type and
*22% probability for resistant) were located on the chro-
mosome between 600,000 and 1,200,000 bp (Fig. 1B)–a region
430 SU ET AL.
FIG. 1. The distribution map of variation sites in resistant Pseudomonas aeruginosa (PA). We used the P. aeruginosa PAO1
genome (NC_002516.2; GI 110645304) as the reference for sequence reassemblage and variation identification of our collected
wild type P. aeruginosa PAO1 and its derivative resistant strain PAO1-CipR. (A) The variation distribution pattern generated
by JMP 9.0 for wild type (top) and resistant (bottom) genomes. The x-axis represents the physical position of the variants in
the genome, in base pairs; the y-axes represent the percentage of variation probability, that is, the average sum of variation
frequencies within a fixed 200,000 bp sequence window. High variability regions A, B, and C have been indicated on the
resistant genome’s pattern and smooth curves have been applied to show the distribution profile for both strains. (B)
Individual variants location map. The three graphs refer to the three high variability regions identified in this study. The x-
axes represent the genomic nucleotide positions of the variants in the genome, in base pairs; the y-axes represent the
percentage of variation frequency, that is, the frequency of each minor variant which differed from the reference sequence,
observed by 454 pyrosequencing. An open circle indicates that common variants appeared in both our collected wild type
PAO1 and the resistant PAO1-CipR genomes, when compared with the reference genome; a gray dot indicates the variation
site appears only in our collected wild type PAO1 genome; and a red dot indicates the variation site appears only in the
resistant strain PAO1-CipR. A blue circle indicates that we selected that variant for ciprofloxacin resistance development
analysis in this study.
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rich in probable bacteriophage coding genes.5 For the PAO1-
CipR genome, the variant distribution was different in the
3,400,000 to 3,800,000 bp region and in the 5,600,000 to
6,000,000 bp region, when compared with the wild type ge-
nome. The smooth curve in Fig. 1A shows that there are
three major variation areas in the resistant genome, which
we labeled as zones A (600,000–1,200,000 bp), B (3,400,000–
3,800,000 bp), and C (5,600,000–6,000,000 bp). Zone A in both
the wild type PAO1 and the resistant PAO1-CipR genomes
showed a relatively similar variation distribution pattern,
while zones B and C showed a more distinguishable varia-
tion pattern between the genomes. We will call these high-
lighted, major variant locations ‘‘resistance-associated high
variability regions’’ and we selected the variants within these
regions for further gene knockout molecular function assay.
The individual variants that we identified from the resistant
and wild type genomes are displayed from low to high
variation frequency in Fig. 1B.
The identified high variability regions and their impact
on resistance development
Once the suspected resistance-associated high variability
regions were determined, we identified potential variants
within those regions as candidates for further gene functional
assay. We first searched the P. aeruginosa PAO1 transposon
mutant library (UW) to see which transposon mutants were
available for further ciprofloxacin exposure response assay
and found a total of 19 variation candidates (Table 2): 4 with
genes appearing with high-variation frequency (> 90%), and
15 with genes appearing with lower variation frequency
(10%–*75%). The gyrA gene in our PAO1-CipR genome ap-
peared as a variation; however, there was no transposon
mutant available for further antibiotic exposure assay. In ad-
dition, we selected two transposon mutant control strains
(Cont-1 and Cont-2 in Table 2 & Fig. 2), which were used as
the protein function assay control sets in our previously
published study, and which our 454 pyrsosequencing data
indicated had no variants in this study; furthermore, their
location outside of our suspected resistance-associated high
variability regions made them appropriate for comparison.
Lastly, candidate D, a probable adhesion protein gene, was
chosen because it showed significant variation frequency in
our pyrosequencing data, but was not located in any of our
suspected high variability regions.
With 48-hr continuous ciprofloxacin exposure (4 ·MIC),
the wild type PAO1 (having a starting MIC of 0.5 mg/ml) and
the two transposon mutant control strains displayed a 48-
fold increase (MIC of 24 mg/ml) when compared with their
initial MICs (Fig. 2). The transposon knockout assay for the
variation sites in zone A yielded diverse results; disruption
of the bacteriophage Pf1 genes (A2 and A3) had little effect
on development of high-level resistance. On the other hand,
transposon disruption within an unknown gene of high
variation frequency (A1) and within a probable transcrip-
tional regulator (A4) seemed to have a significant effect on
resistance development (Fig. 2).
For nearly all of the individual variation sites in zones B
and C, along with candidate D, a probable adhesion protein
gene, there was a 50%–94% reduction in resistance devel-
opment. The only exception was a variation site within a
hypothetical protein-coding gene (C5, Table 2 and Fig. 2).
In all, 15 out of 19 candidate genes containing frequent
mutations, when disrupted, resulted in a reduction in resis-
tance development. Nearly 80% of isolated variation candi-
dates showed a reduction in resistance ability, providing
evidence that resistance development is not the result of indi-
vidual gene variation, but rather is the result of multiple genes
involved in a broad range of interaction regulation mecha-
nisms. For example, of the 15 candidate genes we identified, 6
Table 2. Transposon Mutant Strains Used for Ciprofloxacin Responses Assay with These Genes Knocked Out
Strain Mutant strain IDa Locus tag Gene function defect by transposon inserted
A1 54252 PA0614 Hypothetical protein
A2 13404 PA0720 Helix destabilizing protein of bacteriophage Pf1
A3 14343 PA0724 Probable coat protein A of bacteriophage Pf1
A4 2377 PA0942 Probable transcriptional regulator
A5 48678 PA0963 Aspartyl-tRNA synthetase
A6 31391 PA1035 Hypothetical protein
B1 16199 PA3083 Aminopeptidase N
B2 7116 PA3124 Probable transcriptional regulator
B3 14629 PA3130 Hypothetical protein
B4 45125 PA3228 Probable ATP-binding/permease fusion ABC transporter
B5 5128 PA3282 Hypothetical protein
B6 50330 PA3275 Conserved hypothetical protein
C1 31957 PA5045 Penicillin-binding protein 1A
C2 32019 PA5146 Hypothetical protein
C3 54589 PA5160 Drug efflux transporter
C4 31403 PA5231 Probable ATP-binding/permease fusion ABC transporter
C5 18607 PA5248 Hypothetical protein
C6 19378 PA5262 Alginate biosynthesis protein AlgZ/FimS
D 30423 PA2407 Probable adhesion protein
Cont-1 32477 PA4483 Glu-tRNA(Gln) amidotransferase subunit A
Cont-2 30848 PA5365 Phosphate uptake regulatory protein (PhoU)
aMutant strain ID number is based from the University of Washington Genome Center, Pseudomonas aeruginosa PAO1 transposon mutant
library.
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were correlated with ATP binding/transportation; 2 with
transcription regulation; 1 with transduction regulation; and 1
with translational modification; while only 5 represented genes
of unknown function. These results may have broad implica-
tions in terms of strategy in combating drug resistance: instead
of targeting a specific gene for a new type of antibiotic dis-
covery, a multiple-targets treatment therapymay prove to be a
more promising method for preventing rapid resistance de-
velopment during the repeated antibiotic therapy process.4
The link between the resistance-associated high
variability regions and their gene annotations
Since our study suggested that genome high variability re-
gions associated with resistance development exist in PA, we
then asked: why do these regions appear more pronounced in
the resistant genome? Does any correlation exist between those
discovered gene variants and their gene function? To answer
these questions, we focused on the specific genomic regions to
explore the gene variants and their nearby gene clusters.
As shown in Fig. 3, the highest variation ratio in zone A
was the result of a probable bacteriophage Pf1 gene cluster (12
genes in a row); the genes encoding the helix destabilizing
protein (PA0720) and the coat protein of bacteriophage Pf1
(PA0724) are the major variation sites. The variants at PA0614
(strain A1 represented its transposon mutant), a hypothetical
protein-encoded gene located in front of another probable
bacteriophage protein-encoded gene cluster (ranging from
677,000 to 683,000 bp), showed an 84% reduction in the ability
to develop resistance. The variants at PA0942 (a transcrip-
tional regulator, strain A4) and PA1035 (a hypothetical pro-
tein, strain A6) both showed a 75% reduction in resistance.
In zone B, the resistant genome showed a distinguishable
variation distribution difference when comparedwith the wild
type genome: we discovered eight unique variants, including
the variation in gyrA, in this zone. PA3083 (aminopeptidaseN),
PA3124 (a probable transcriptional regulator), and PA3130 (a
hypothetical protein) were located in the 3,460,000 to
3,510,000 bp region of the genome, and this region included 10
nearby genes related to general secretion pathways. In the
3,530,000 to 3,560,000 bp region, the variants of the gyrA and
hisH2 genes were found. It is known that a gyrAmutation will
increase ciprofloxacin resistance in PA, and the hisH2 gene,
located within a lipopolysaccharide biosynthetic cluster, may
be associated with amino acid transport and the formation of
biofilm.8 Unfortunately, these two genes have no transposon
mutants available for antibiotic exposure assay, so we could
not evaluate whether mutations in these gene contribute to
resistance sensitivity in PA. In the 3,610,000to 3,680,000 bp re-
gion, PA3228 (a probable ATP-binding/permease fusion ABC
transporter), and PA3275 and PA3282 (hypothetical proteins)
had nearby genes that function as ATP-dependent DNA heli-
cases and probable two-component sensors.
In zone C, PA5045 (a penicillin-binding protein) showed
high gene variation potential but its transposonmutant did not
suggest that it had a significant reduction in resistance-
acquiring ability. The variants of PA5146 (a hypothetical pro-
tein) and PA5160 (a drug efflux transporter) encoding genes
were located in the 5,790,000 to 5,810,000 bp region of the
genome, which included a probable ATP-binding component
of an ABC transporter, a probable permease of an ABC trans-
porter, and a probable outer membrane protein precursor and
multidrug resistance protein gene cluster. Interestingly, mul-
tiple drug-resistant protein genes are clustered in this region.
Moreover, there are variations identified at PA5231 (a probable
ATP- binding/permease fusion ABC transporter), PA5248
(a hypothetical protein), and PA5262 (an Alginate biosynthesis
protein) located in the genome at 5,886,000 to 5,923,000bp: our
genome sequence analysis showed that variants were identi-
fied within a gene cluster linked with an ATP-binding cassette
superfamily and two-component signal transduction systems.
Most of the variants located in Zone C showed an interesting
linkage between energy-dependent transportation and signal
transduction systems, which provides further support of the
results found in our previous study.26
Discussion
In summary, our data suggest there are three potential
high variability regions in PA associated with ciprofloxacin
FIG. 2. Ciprofloxacin response profile for gene variant transposon mutants versus controls. After 24- and 48-hr cipro-
floxacin exposure in liquid medium at 4· the starting minimal inhibitory concentration (MIC) (0.5 mg/ml), the wild type,
control strains, and candidate strains were retested to determine MIC levels relative to the starting level. Within the 24-hr
treatment, all transposon mutants showed a reduction in MIC when compared with the wild type PAO1 and the control
strains. After the 48-hr treatment, the A2, A3, A5, and C5 transposon mutants showed no reduction (or significant reduction)
effect for ciprofloxacin resistance development. The panels A,B, and C, along with candidate D, represent the high variability
regions and the indicated individual variants in Fig. 1. MIC data are averaged from duplicate Etest experiments.
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resistance development. In zone A, a high variation profile
existed for both the wild type and resistant genomes, re-
garding the probable bacteriophage protein-coding genes.
However, based on our transposon gene knockout functional
assay, the data did not show a strong link with resistance
development in PA. In zone B, the resistant genome dis-
played a variation profile distinguishable from that of the
wild type, and those selected genes with potential high
variation were closely related with general secretion path-
ways, ATP-dependent DNA helicases, and probable two-
component sensors. The most unusual variation region in the
resistant genome was zone C, which showed the identified
variant genes having a potential functional link with an ATP-
binding cassette superfamily and two-component signal
transduction systems.
It is worth noting that in our previous study, we took a
proteomics approach to identify upregulation of phosphoryla-
tion on two proteins (succinate-semialdehyde dehydrogenase
andmethylmalonate-semialdehydedehydrogenase),whichwe
suspected were part of an energy production regulation path-
way that might be involved with resistance development.26
These two identified proteins were not located in any of our
suggested high variability regions in PA; however, theymay be
associated with the variation candidates we discovered in this
study since some of them showed a close relationship with
signal transduction and energy-related pathways.
Meanwhile, a recent study that used a deep-sequencing
procedure (the Tn-seq circle method) to detect large numbers
of transposon mutants in PA identified 117 genes associated
with intrinsic tobramycin resistance.10 A group of mutations
in 28 genes led to at least four-fold decreases in the to-
bramycin MICs; of these, 13 were previously identified re-
sistance genes and 15 were newly identified, covering the
gene functions of transport and amino acid metabolism, and
including transcriptional regulators and peptidyl-prolyl
isomerases. Both our study and the work of Gallagher et al.
revealed a multiplicity of new genes associated with resis-
tance in PA, though the Tn-seq approach provided a ge-
nome-wide identification of intrinsic resistance genes,10
while our study identified the existence of genomic high
variability regions after PA was exposed to ciprofloxacin. Of
the 28 intrinsic resistance genes identified by Gallagher et al.,
3 were located inside our high variability regions (PA5199
and PA5200 in Zone C and PA3194 in Zone B). In light of our
observations and these published data, we also suspected
that an adaptive selection pressure that enriched the variants
might provide an increased fitness advantage for those cells
continuously exposed to ciprofloxacin. For example, the high
level resistance of isolated PAO1-CipR in this study may be a
result of the gyrA mutation and a group of newly-identified
adaptive variation genes that together compensate for the
fitness cost of resistance. So we may have identified a group
FIG. 3. Genome comparative analysis of the distribution of sequence variants and the association with their genes’ func-
tional annotations. The PA genome diagrams shown here were generated by GBrowse from Pseudomonas Genome Database
v2 (www.pseudomonas.com/gbrowse_index.jsp). The three main high variability regions are identified by the letters A, B,
and C. The gene annotations (noted in dark green) were from the PseudoCAP genes (Pseudomonas aeruginosa Community
Annotation Project). Red stars indicate the variants’ locations and which had transposon mutants available. Operon pre-
dictions found using PathoLogic are shown as light blue arrows, representing the transcription units, while red arrows
indicate that those variants are in an operon. The gyrA and hisH2 genes shown in zone B did not have a transposon mutant
available for antibiotic exposure assay.
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of genes in the high variability regions that potentially link to
a set of pathways that favor an increase of growth fitness
during antibiotic exposure. This idea is supported by the fact
that when we used transposons to truncate a single gene in
these positions, this increased fitness advantage was elimi-
nated, seemingly because the variants involved in the path-
ways might act together to develop resistance.
Resistance in PA is a multiregulation process involving
preexisting cellular pathways26 and accumulated gene mu-
tations (the results shown in this study). By performing
comparative genome analysis with 454 pyrosequencing
technology, we found three main potential high variability
regions in PA, and from the transposon gene functional as-
say, we found that the physical locations of the genomic
variations impacted the development of ciprofloxacin resis-
tance differently. In this study, 454 pyrosequencing tech-
nology allowed us to explore whether any potential variation
regions exist that may result in resistance development. By
using this approach, we generated gene variation distribu-
tion maps (Fig. 1A, B) for the wild type genome and resistant
genome, which showed variation profiles suggesting that a
variety of evolutionary paths could drive PA to become re-
sistant to antibiotic treatment. Our results indicate that not
only will the high variation sites be primary factors that
cause a rise in the level of resistance, but also that those
lower potential variations represent all theoretical genome
mutation sites which may also impact resistance develop-
ment once the mutation occurs. Moreover, we also suspect
that there are many undiscovered variations that may be
present in the sequence gap regions for which we could not
gather data. For example, we noticed several annotated ef-
flux pump sequences showing unique sequencing gaps
ranging from 50 to 700 bp in the resistant genome, which
were not discovered in our wild type strain’s genome.
The variation distribution maps that we generated in this
study will be valuable tools for in-depth comparisons when
more exposure genome variation sequences become avail-
able. That information will allow researchers to uncover the
resistance development network on a more comprehensive
level, ultimately helping to improve antibiotic therapies and
combat the rapid rise of drug resistance.
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